Advanced search
1 file | 261.66 KB Add to list

Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck

(2010) ANNALS OF ONCOLOGY. 21(10). p.1967-1973
Author
Organization
Abstract
Patients and methods: The European Organisation for Research and Treatment of Cancer QoL Questionnaire-Core 30 (QLQ-C30) and QLQ-Head and Neck 35 (QLQ-H&N35) module were used to assess QoL. Results: Of 442 patients randomly assigned, 291 (QLQ-C30) and 289 (QLQ-H&N35) patients completed at least one evaluable questionnaire. For QLQ-C30, cycle 3 and month 6 mean scores for platinum-fluorouracil plus cetuximab were not significantly worse than those for platinum-fluorouracil. Pattern-mixture analysis demonstrated a significant improvement in the global health status/QoL score in the cetuximab arm (P = 0.0415) but no treatment differences in the social functioning scale. For QLQ-H&N35, the mean score for the cetuximab arm was not significantly worse than that for the chemotherapy arm for all symptom scales at all post-baseline visits. At cycle 3, some symptom scores significantly favored the cetuximab arm (pain, swallowing, speech problems, and social eating). Conclusion: Adding cetuximab to platinum-fluorouracil does not adversely affect the QoL of patients with recurrent and/or metastatic SCCHN.
Keywords
TRIAL, QLQ-H-AND-N35, COLORECTAL-CANCER, recurrent and metastatic, quality of life, head and neck cancer, cetuximab, cisplatin, RADIOTHERAPY, COMBINATION, CISPLATIN, SURVIVAL

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 261.66 KB

Citation

Please use this url to cite or link to this publication:

MLA
Mesía, R, F Rivera, A Kawecki, et al. “Quality of Life of Patients Receiving Platinum-based Chemotherapy Plus Cetuximab First Line for Recurrent And/or Metastatic Squamous Cell Carcinoma of the Head and Neck.” ANNALS OF ONCOLOGY 21.10 (2010): 1967–1973. Print.
APA
Mesía, R., Rivera, F., Kawecki, A., Rottey, S., Hitt, R., Kienzer, H., Cupissol, D., et al. (2010). Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck. ANNALS OF ONCOLOGY, 21(10), 1967–1973.
Chicago author-date
Mesía, R, F Rivera, A Kawecki, Sylvie Rottey, R Hitt, H Kienzer, D Cupissol, et al. 2010. “Quality of Life of Patients Receiving Platinum-based Chemotherapy Plus Cetuximab First Line for Recurrent And/or Metastatic Squamous Cell Carcinoma of the Head and Neck.” Annals of Oncology 21 (10): 1967–1973.
Chicago author-date (all authors)
Mesía, R, F Rivera, A Kawecki, Sylvie Rottey, R Hitt, H Kienzer, D Cupissol, D De Raucourt, M Benasso, P Koralewski, JP Delord, C Bokemeyer, D Curran, A Gross, and JB Vermorken. 2010. “Quality of Life of Patients Receiving Platinum-based Chemotherapy Plus Cetuximab First Line for Recurrent And/or Metastatic Squamous Cell Carcinoma of the Head and Neck.” Annals of Oncology 21 (10): 1967–1973.
Vancouver
1.
Mesía R, Rivera F, Kawecki A, Rottey S, Hitt R, Kienzer H, et al. Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck. ANNALS OF ONCOLOGY. 2010;21(10):1967–73.
IEEE
[1]
R. Mesía et al., “Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck,” ANNALS OF ONCOLOGY, vol. 21, no. 10, pp. 1967–1973, 2010.
@article{1195838,
  abstract     = {Patients and methods: The European Organisation for Research and Treatment of Cancer QoL Questionnaire-Core 30 (QLQ-C30) and QLQ-Head and Neck 35 (QLQ-H&N35) module were used to assess QoL.
Results: Of 442 patients randomly assigned, 291 (QLQ-C30) and 289 (QLQ-H&N35) patients completed at least one evaluable questionnaire. For QLQ-C30, cycle 3 and month 6 mean scores for platinum-fluorouracil plus cetuximab were not significantly worse than those for platinum-fluorouracil. Pattern-mixture analysis demonstrated a significant improvement in the global health status/QoL score in the cetuximab arm (P = 0.0415) but no treatment differences in the social functioning scale. For QLQ-H&N35, the mean score for the cetuximab arm was not significantly worse than that for the chemotherapy arm for all symptom scales at all post-baseline visits. At cycle 3, some symptom scores significantly favored the cetuximab arm (pain, swallowing, speech problems, and social eating).
Conclusion: Adding cetuximab to platinum-fluorouracil does not adversely affect the QoL of patients with recurrent and/or metastatic SCCHN.},
  author       = {Mesía, R and Rivera, F and Kawecki, A and Rottey, Sylvie and Hitt, R and Kienzer, H and Cupissol, D and De Raucourt, D and Benasso, M and Koralewski, P and Delord, JP and Bokemeyer, C and Curran, D and Gross, A and Vermorken, JB},
  issn         = {0923-7534},
  journal      = {ANNALS OF ONCOLOGY},
  keywords     = {TRIAL,QLQ-H-AND-N35,COLORECTAL-CANCER,recurrent and metastatic,quality of life,head and neck cancer,cetuximab,cisplatin,RADIOTHERAPY,COMBINATION,CISPLATIN,SURVIVAL},
  language     = {eng},
  number       = {10},
  pages        = {1967--1973},
  title        = {Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck},
  url          = {http://dx.doi.org/10.1093/annonc/mdq077},
  volume       = {21},
  year         = {2010},
}

Altmetric
View in Altmetric
Web of Science
Times cited: